Clinical trial Recruiting at 1 site Observational Ages 45 to 80

Assessing major complications in patients with thoracic aortic aneurysm

Official title: Predicting Moderate Thoracic Aortic Aneurysm Evolution: a Longitudinal Study of Systemic Factors in Patients Free of Connective Tissue Disease. .

Run by University Hospital, Lille · NCT05395598 · Data updated 2026-11-12

This study is trying to see how often serious problems happen in people with small to moderate thoracic aortic aneurysms over five years and what factors might affect their condition.

Quick facts

Study typeObservational
Ages45 Years to 80 Years
SexAll
Enrollment320 (estimated)
SponsorUniversity Hospital, Lille
Academic / other
Locations1 site (Lille, Please Choose...)
StatusRecruiting
StartedApril 18, 2024
Main results expectedApril 18, 2031
Study endsOctober 2031
Registry record updatedMay 15, 2026
Trial IDNCT05395598 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals with a documented thoracic aortic aneurysm greater than 40 mm who can commit to a five-year follow-up.

Probably not a fit

Patients with significant comorbidities, advanced aneurysm progression, or a history of aortic surgery may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the incidence of major complications in patients diagnosed with small to moderate thoracic aortic aneurysms over a five-year follow-up period. It will investigate various systemic factors, such as high blood pressure and sleep disorders, that may influence the progression of the aneurysm. Participants will undergo regular imaging and clinical assessments to monitor their condition and identify any complications that arise. The study seeks to fill the gap in existing data regarding the risks associated with thoracic aortic aneurysms.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the management and monitoring of patients with thoracic aortic aneurysms, potentially improving patient outcomes.

How similar studies have gone: While there is limited data on the specific incidence of complications in small to moderate thoracic aortic aneurysms, similar observational studies have provided valuable insights into aneurysm management.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Documentation of an aortic root aneurysm \> 40 mm
* Agreement to participate to a longitudinal study and available for a 5 years follow-up

Exclusion Criteria:

* Presence of comorbidities or pathology with a prognosis of less than 1 year
* Personal or family history of genetically documented elastic tissue disease or patient meeting the GAND clinical criteria suggestive of Marfan disease
* High-grade mitra-aortic valve disease, even if asymptomatic
* Unbalanced hypertension ≥ 180/110 mmHg
* Aneurysm (regardless of thoracic or abdominal location) ≥ 50 mm
* Aneurysm (regardless of thoracic or abdominal location) with documented progression of more than 5 mm over one year
* History of aortic surgery or endovascular intervention and history of type B aortic dissection of medical treatment
* Renal insufficiency on dialysis, or GFR\< 30 ml/mn (CKD-EPI)

Where it's running

  • CHU Lille
    Lille, Please Choose..., France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.